Tetrakit Technologies ApS - CVR: 42094943

2023, DKK

28.06.2024

Bruttoresultat

-4.414'

Primær drift

-6.838'

Årets resultat

-6.034'

Aktiver

3.391'

Kortfristede aktiver

3.391'

Egenkapital

-6.536'

Afkastningsgrad

-202 %

Soliditetsgrad

-193 %

Likviditetsgrad

+500%

Resultat

28.06.2024

Årsrapport	2023 28.06.2024	2022 14.06.2023	2021 28.04.2022
Nettoomsætning			0
Bruttoresultat	-4.413.722	-987.987	0
Resultat af primær drift	-6.838.497	-2.458.060	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0
Finansielle indtægter	102	0	0
Finansieringsomkostninger	-236.240	-122.251	-2.812
Andre finansielle omkostninger	0	0	0
Resultat før skat	-7.074.635	-2.580.311	-2.812
Resultat	-6.033.694	-2.235.527	-2.812
Forslag til udbytte	0	0	0

Aktiver

28.06.2024

Årsrapport	2023 28.06.2024	2022 14.06.2023	2021 28.04.2022
Kortfristede varebeholdninger	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.628.509	432.012	0
Likvider	1.762.965	3.686.915	57.188
Kortfristede aktiver	3.391.474	4.118.927	57.188
Immaterielle aktiver og goodwill	0	0	0
Finansielle anlægsaktiver	0	0	0
Materielle aktiver	0	0	0
Langfristede aktiver	0	0	0
Aktiver	3.391.474	4.118.927	57.188

Aktiver

28.06.2024

Passiver

28.06.2024

Årsrapport	2023 28.06.2024	2022 14.06.2023	2021 28.04.2022
Forslag til udbytte	0	0	0
Egenkapital	-6.535.783	-502.089	57.188
Hensatte forpligtelser	0	0	0
Langfristet gæld til banker	0	0	0
Anden langfristet gæld		0	0
Leverandører af varer og tjenesteydelser	394.228	345.639	0
Kortfristede forpligtelser	597.572	526.002	0
Gældsforpligtelser	9.927.257	4.621.016	0
Forpligtelser	9.927.257	4.621.016	0
Passiver	3.391.474	4.118.927	57.188

Passiver

28.06.2024

Nøgletal

28.06.2024

Årsrapport	2023 28.06.2024	2022 14.06.2023	2021 28.04.2022
Afkastningsgrad	-201,6 %	-59,7 %	Na.
Dækningsgrad	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.
Egenkapitals-forretning	92,3 %	445,2 %	-4,9 %
Payout-ratio	Na.	Na.	Na.
Gældsdæknings-nøgletal	-2.894,7 %	-2.010,7 %	Na.
Soliditestgrad	-192,7 %	-12,2 %	100,0 %
Likviditetsgrad	567,5 %	783,1 %	Na.

Resultat

28.06.2024

Gæld

28.06.2024

Årsrapport

28.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 28.06.2024)

Information om virksomhedens regnskabsklasse:The annual report has been presented in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, with the adoption of individual rules from class C.

Oplysning om pantsætninger og sikkerhedsstillelser:5. Collaterals and securities No securities or mortgages exist at the balance sheet date.

Beretning

28.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-06-17

Ledelsespåtegning: Today, Management has considered and adopted the Annual Report of Tetrakit Technologies ApS for the financial year 1 January 2023 - 31 December 2023. The Annual Report is presented in accordance with the Danish Financial Statements Act. In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023. In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review. We recommend that the Annual Report be adopted at the Annual General Meeting. Copenhagen, 17 June 2024 Management Andreas Tue Ingemann Jensen Umberto Maria Battisti Christian Bernard Matthijs Poulie Managing director Matthias Manfred Herth Vladimir Shalgunov Board of Directors Andreas Tue Ingemann Jensen Umberto Maria Battisti Christian Bernard Matthijs Poulie Matthias Manfred Herth Vladimir Shalgunov

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, Management has considered and adopted the Annual Report of Tetrakit Technologies ApS for the financial year 1 January 2023 - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company's principal activities The Company's principal activities consist in develops radiopharmaceuticals for the diagnosis and treatment of cancer.